TP53 and cancer: The simplest way to inactivate p53 is to mutate and/or lose the wild-type copy of the gene, yet while this happens in more than fifty percent of all cancers, why cancers from certain tissues or indeed molecularly defined sub-types selectively evolve to maintain wild-type p53 and suppress activity through altering upstream activator/repressors or downstream effectors to affect cell fate outcomes (e.g., arrest vs. death) remains poorly understood.